Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Tax Provisions (2017 - 2025)

Corcept Therapeutics' Tax Provisions history spans 9 years, with the latest figure at -$14.4 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 1313.18% year-over-year to -$14.4 million; the TTM value through Dec 2025 reached -$33.2 million, down 264.43%, while the annual FY2025 figure was -$33.2 million, 263.62% down from the prior year.
  • Tax Provisions for Q4 2025 was -$14.4 million at Corcept Therapeutics, down from -$4.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $7.7 million in Q4 2022 and bottomed at -$14.4 million in Q4 2025.
  • The 5-year median for Tax Provisions is $4.6 million (2021), against an average of $1.6 million.
  • The largest annual shift saw Tax Provisions soared 412.55% in 2023 before it plummeted 1313.18% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $4.7 million in 2021, then soared by 63.46% to $7.7 million in 2022, then decreased by 29.52% to $5.4 million in 2023, then crashed by 78.11% to $1.2 million in 2024, then tumbled by 1313.18% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Tax Provisions are -$14.4 million (Q4 2025), -$4.4 million (Q3 2025), and -$3.5 million (Q2 2025).